Strategic ADC focus LegoChem Biosciences is actively advancing antibody-drug conjugate (ADC) therapies across oncology and related modalities, with recent partnerships and licensing deals (including Janssen and Samsung Biologics collaborations). Leverage opportunities by offering CDMO/CMO services, ADC payload optimization, linker chemistry expertise, and customized conjugation platforms to support ADC development and manufacturing.

Partnerships and licensing The company has a track record of licensing agreements and strategic collaborations with global players (Elthera AG, Janssen, Samsung Biologics, Orion Group stake). Explore co-development, licensing, and collaboration models, as well as joint ventures or exclusive rights for novel ADCs or antibody platforms to expand market reach.

Expanded manufacturing potential With Samsung Biologics as a partner and a focus on ADC/PDC programs, LegoChem is positioned for manufacturing scale-up opportunities. Target conversations around GMP-ready supply, process development, cGMP manufacturing for complex biologics, and late-stage clinical manufacturing support.

Pipeline monetization LCB maintains diverse programs in antibiotics, anti-coagulants, oncology, and ADC/PDC, including LCB84 under Janssen license. Identify opportunities to license or co-develop additional assets, or to provide platform access for discovery, optimization, or translational studies to accelerate partner portfolios.

Strategic growth signals Significant funding and a notable shareholding shift (Orion Group stake) indicate strong investor confidence and potential for inflection points in collaboration-friendly expansion. Position as a partner to support fundraising-backed expansions, late-stage trials, or strategic acquisitions related to ADC platform capabilities.